Aclarion (Aclarion) Debt-to-Equity : -1.55 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Aclarion Debt-to-Equity?

Aclarion's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.13 Mil. Aclarion's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Aclarion's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.73 Mil. Aclarion's debt to equity for the quarter that ended in Dec. 2023 was -1.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aclarion's Debt-to-Equity or its related term are showing as below:

ACON' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.55 Med: -0.34 Max: -0.3
Current: -1.55

During the past 5 years, the highest Debt-to-Equity Ratio of Aclarion was -0.30. The lowest was -1.55. And the median was -0.34.

ACON's Debt-to-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.485 vs ACON: -1.55

Aclarion Debt-to-Equity Historical Data

The historical data trend for Aclarion's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Debt-to-Equity Chart

Aclarion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.30

-0.34

-0.35

-1.55

Aclarion Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										-	-	11.90	-0.88	-1.55

Competitive Comparison of Aclarion's Debt-to-Equity

For the Health Information Services subindustry, Aclarion's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclarion's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aclarion's Debt-to-Equity falls into.

Aclarion Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aclarion's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.126	+	0)	/	-0.728
	=	-1.55

Aclarion's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.126	+	0)	/	-0.728
	=	-1.55

Aclarion (NAS:ACON) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aclarion Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aclarion's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclarion (Aclarion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021

Website

http://www.aclarion.com

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Executives

John Paul Lorbiecki	officer: Chief Financial Officer	238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness	director, officer: Chief Executive Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond	officer: Chief Strategy Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch	director	1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann	director	130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann	director, officer: Executive Chairman	8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks	10 percent owner	811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc	10 percent owner	7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc	10 percent owner	1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart	director	951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira	director	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal	director	C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404